David A. Siegel Arrowhead Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 723,800 shares of ARWR stock, worth $11.4 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
723,800
Previous 430,700
68.05%
Holding current value
$11.4 Million
Previous $8.1 Million
13.88%
% of portfolio
0.02%
Previous 0.02%
Shares
23 transactions
Others Institutions Holding ARWR
# of Institutions
294Shares Held
97.7MCall Options Held
306KPut Options Held
432K-
Black Rock Inc. New York, NY15.7MShares$247 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$208 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$175 Million2.29% of portfolio
-
State Street Corp Boston, MA7MShares$110 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$82.4 Million1.32% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.67B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...